Peripheral artery disease is an independent predictor of mortality after implantable cardioverter-defibrillator implantation in patients with severe left ventricular dysfunction.

Autor:	Skeik N; Vascular Medicine, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA nedaa.skeik@allina.com., McGriff DM; Minneapolis Heart Institute Foundation, Minneapolis, MN, USA., Katsiyiannis WT; Electrophysiology, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA., Sullivan TM; Vascular Surgery, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA., Mugglin AS; Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, USA., Retel LM; Minneapolis Heart Institute Foundation, Minneapolis, MN, USA., Hauser RG; Cardiology, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.
Jazyk:	angličtina
Zdroj:	Angiology [Angiology] 2014 Jul; Vol. 65 (6), pp. 507-11. Date of Electronic Publication: 2013 Aug 21.
DOI:	10.1177/0003319713499607
Abstrakt:	The impact of peripheral artery disease (PAD) on survival in implantable cardioverter defibrillator (ICD) patients is poorly understood. Thus, we assessed the risk of PAD in our adult ICD patients with left ventricular dysfunction (ejection fraction [EF] ≤35%). Survival was estimated with Kaplan-Meier method and compared by the log-rank test; a Cox proportional hazards model assessed the effects of clinical variables on survival. Average age and EF of 1399 patients were 67.0 ± 12.1 years and 23.8% ± 7.2%, respectively. The ICD patients with PAD had significantly worse survival than those without (unadjusted P < .0001). The multivariate predictors of survival at implant were (hazard ratio, HR [95% confidence interval]) age (HR 1.05 [1.04-1.07] P < .0001), PAD (HR 2.07 [1.53-2.80] P < .0001), class III/IV heart failure (HR 1.36 [1.06-1.76] P = .016), creatinine 1.4-2.0 mg/dL (HR 1.36 [1.05-1.76] P = .019), and creatinine ≥2.0 mg/dL (HR 2.01 [1.42-2.85] P < .0001). The PAD is an independent predictor of mortality and should be considered in the preimplant risk assessment. (© The Author(s) 2013.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu